Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
This study has been completed.
Information provided by (Responsible Party):
First received: September 6, 2013
Last updated: August 27, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2014|
|Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||August 13, 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025.